Journal of clinical lipidology · 2026
Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biolo Marta, Lupo Maria Giovanna, Marodin Giorgia, Portinari Camilla, Zambon Alberto, Bertocco Sandra, Previato Lorenzo, Simioni Paolo, Ferri Nicola, Zambon Sabina
Аннотация
BACKGROUND: Genetic variants of the low-density lipoprotein (LDL) receptor cause homozygous familial hypercholesterolemia (HoFH). Disease-specific treatment options include lipoprotein apheresis and lomitapide, and more recently, the angiopoietin-like 3 (ANGPTL3)-targeting monoclonal antibody evinacumab.
OBJECTIVE: We evaluated the efficacy and safety of this therapeutic combination in patients with HoFH.
METHODS: We report a single-center, real-world clinical experience including 6 patients with HoFH, 4 of whom were pediatric, with persistently elevated LDL-cholesterol (LDL-C) (>130 mg/dL), despite optimized lipid-lowering therapy, including lipoprotein apheresis and lomitapide. These patients received intravenous evinacumab at 15 mg/kg every 4 weeks on top of stable background lipid-lowering therapy, including lomitapide, and after discontinuation of lipoprotein apheresis.
RESULTS: At baseline, immediately before evinacumab initiation, mean LDL-C was 289.6 ± 80.6 mg/dL (7.25 ± 2.08 mmol/L). Treatment with evinacumab resulted in a sustained reduction in LDL-C by 55.0% ± 12.5% through week 48. In addition, evinacumab reduced apolipoprotein B (ApoB) by 46.0% ± 10.5%, total cholesterol by 53.1% ± 11.4%, and triglycerides by 51.9% ± 8.2%. Plasma ANGPTL3 levels approximately doubled, whereas proprotein convertase subtilisin/kexin type 9 decreased modestly, reaching a -15% at week 24. The combination of evinacumab and lomitapide was generally well tolerated throughout the study period with no serious treatment-emergent adverse events. One patient experienced a delayed infusion reaction, and another a transient headache and flu-like symptoms.
CONCLUSION: Evinacumab added to lomitapide-based background lipid-lowering therapy was associated with marked reductions in LDL-C, ApoB, and other lipid parameters, with a favorable safety profile. These findings support the potential clinical usefulness of the evinacumab/lomitapide combination in both pediatric and adult patients with HoFH, although decisions regarding lipoprotein apheresis should remain individualized.
OBJECTIVE: We evaluated the efficacy and safety of this therapeutic combination in patients with HoFH.
METHODS: We report a single-center, real-world clinical experience including 6 patients with HoFH, 4 of whom were pediatric, with persistently elevated LDL-cholesterol (LDL-C) (>130 mg/dL), despite optimized lipid-lowering therapy, including lipoprotein apheresis and lomitapide. These patients received intravenous evinacumab at 15 mg/kg every 4 weeks on top of stable background lipid-lowering therapy, including lomitapide, and after discontinuation of lipoprotein apheresis.
RESULTS: At baseline, immediately before evinacumab initiation, mean LDL-C was 289.6 ± 80.6 mg/dL (7.25 ± 2.08 mmol/L). Treatment with evinacumab resulted in a sustained reduction in LDL-C by 55.0% ± 12.5% through week 48. In addition, evinacumab reduced apolipoprotein B (ApoB) by 46.0% ± 10.5%, total cholesterol by 53.1% ± 11.4%, and triglycerides by 51.9% ± 8.2%. Plasma ANGPTL3 levels approximately doubled, whereas proprotein convertase subtilisin/kexin type 9 decreased modestly, reaching a -15% at week 24. The combination of evinacumab and lomitapide was generally well tolerated throughout the study period with no serious treatment-emergent adverse events. One patient experienced a delayed infusion reaction, and another a transient headache and flu-like symptoms.
CONCLUSION: Evinacumab added to lomitapide-based background lipid-lowering therapy was associated with marked reductions in LDL-C, ApoB, and other lipid parameters, with a favorable safety profile. These findings support the potential clinical usefulness of the evinacumab/lomitapide combination in both pediatric and adult patients with HoFH, although decisions regarding lipoprotein apheresis should remain individualized.